Breast Cancer Statistics, 2022.
Angela N GiaquintoHyuna SungKimberly D MillerJoan L KramerLisa A NewmanAdair MinihanAhmedin JemalRebecca L SiegelPublished in: CA: a cancer journal for clinicians (2022)
This article is the American Cancer Society's update on female breast cancer statistics in the United States, including population-based data on incidence, mortality, survival, and mammography screening. Breast cancer incidence rates have risen in most of the past four decades; during the most recent data years (2010-2019), the rate increased by 0.5% annually, largely driven by localized-stage and hormone receptor-positive disease. In contrast, breast cancer mortality rates have declined steadily since their peak in 1989, albeit at a slower pace in recent years (1.3% annually from 2011 to 2020) than in the previous decade (1.9% annually from 2002 to 2011). In total, the death rate dropped by 43% during 1989-2020, translating to 460,000 fewer breast cancer deaths during that time. The death rate declined similarly for women of all racial/ethnic groups except American Indians/Alaska Natives, among whom the rates were stable. However, despite a lower incidence rate in Black versus White women (127.8 vs. 133.7 per 100,000), the racial disparity in breast cancer mortality remained unwavering, with the death rate 40% higher in Black women overall (27.6 vs. 19.7 deaths per 100,000 in 2016-2020) and two-fold higher among adult women younger than 50 years (12.1 vs. 6.5 deaths per 100,000). Black women have the lowest 5-year relative survival of any racial/ethnic group for every molecular subtype and stage of disease (except stage I), with the largest Black-White gaps in absolute terms for hormone receptor-positive/human epidermal growth factor receptor 2-negative disease (88% vs. 96%), hormone receptor-negative/human epidermal growth factor receptor 2-positive disease (78% vs. 86%), and stage III disease (64% vs. 77%). Progress against breast cancer mortality could be accelerated by mitigating racial disparities through increased access to high-quality screening and treatment via nationwide Medicaid expansion and partnerships between community stakeholders, advocacy organizations, and health systems.
Keyphrases
- epidermal growth factor receptor
- breast cancer risk
- risk factors
- polycystic ovary syndrome
- endothelial cells
- tyrosine kinase
- pregnancy outcomes
- cardiovascular events
- advanced non small cell lung cancer
- magnetic resonance imaging
- squamous cell carcinoma
- mental health
- type diabetes
- metabolic syndrome
- cardiovascular disease
- healthcare
- machine learning
- young adults
- cervical cancer screening
- big data
- childhood cancer
- magnetic resonance
- computed tomography
- artificial intelligence
- deep learning
- free survival